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A B S T R A C TEconomic evaluations of health interventions pose a particular chal-
lenge for reporting. There is also a need to consolidate and update
existing guidelines and promote their use in a user friendly manner.
The Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) statement is an attempt to consolidate and update previous
health economic evaluation guidelines efforts into one current, useful
reporting guidance. The primary audiences for the CHEERS statement
are researchers reporting economic evaluations and the editors and
peer reviewers assessing them for publication.
The need for new reporting guidance was identified by a survey of
medical editors. A list of possible items based on a systematic review
was created. A two round, modified Delphi panel consisting of
representatives from academia, clinical practice, industry, govern-
ment, and the editorial community was conducted. Out of 44 candi-
date items, 24 items and accompanying recommendations were
developed. The recommendations are contained in a user friendly,see front matter Copyright & 2013, International
r HS Journals, Inc.
.1016/j.jval.2013.02.010
joint publication by Value in Health, BJOG: An Int
Cost Effectiveness and Resource Allocation, The Euro
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pondence to: Don Husereau, 879 Winnington Ave24 item checklist. A copy of the statement, accompanying checklist,
and this report can be found on the ISPOR Health Economic Evalua-
tions Publication Guidelines Task Force website: (www.ispor.org/Task-
Forces/EconomicPubGuidelines.asp).
We hope CHEERS will lead to better reporting, and ultimately,
better health decisions. To facilitate dissemination and uptake, the
CHEERS statement is being co-published across 10 health economics
and medical journals. We encourage other journals and groups, to
endorse CHEERS. The author team plans to review the checklist for an
update in five years.
Keywords: biomedical research/methods, biomedical research/
standards, costs and cost analysis, guidelines as topic/standards,
humans, publishing/standards.
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Research (ISPOR). Published by Elsevier HS Journals, Inc.Health economic evaluations are conducted to inform resource
allocation decisions. Economic evaluation has been defined as
‘‘the comparative analysis of alternative courses of action in terms
of both their costs and their consequences.’’ [1] All economic
evaluations assess costs, but approaches to measuring and valuing
the consequences of health interventions may differ (see Box 1).
Economic evaluations have been widely applied in health policy,
including the assessment of prevention programmes (such as vacci-
nation, screening, and health promotion), diagnostics, treatment
interventions (such as drugs and surgical procedures), organisationof care, and rehabilitation. Economic evaluations are increasingly
being used for decision making and are an important component of
programmes for health technology assessment internationally [2].Reporting Challenges and Shortcomings in Health
Economic Evaluations
Compared with clinical studies, which report the consequences of
an intervention only, economic evaluations require more reporting
space for additional items, such as resource use, costs, preferenceSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
ernational Journal of Obstetrics and Gynaecology, BMC Medicine, BMJ,
pean Journal of Health Economics, International Journal of Technology
onomics. Each publisher holds its own copyright.
nue, Ottawa, ON, Canada K2B 5C4.
Box 1 – Forms of economic evaluation.
Specific forms of analysis reflect different approaches to
evaluating the consequences of health interventions.
Health consequences may be estimated from a single
analytical (experimental or non-experimental) study,
a synthesis of studies, mathematical modelling, or a
combination of modelling and study information.
Cost consequences analysis examines costs and conse-
quences without attempting to isolate a single conse-
quence or aggregate consequences into a single measure
Cost minimisation analysis (CMA)—The consequences
of compared interventions are required to be equivalent,
and only relative costs are compared
Cost effectiveness analysis (CEA) measures consequences
in natural units, such as life years gained, disability days
avoided, or cases detected. In a variant of CEA, often
called cost utility analysis, consequences aremeasured in
terms of preference-based measures of health, such as
quality adjusted life years or disability adjusted life years.
Cost benefit analysis—Consequences are valued in
monetary units.
Readers should be aware that an economic evaluation
might be referred to as a ‘‘cost effectiveness analysis’’ or
‘‘cost benefit analysis’’ even if it does not strictly adhere
to the definitions above. Multiple forms may also exist
within a single evaluation. Different forms of analysis
provide unique advantages or disadvantages for deci-
sion making. The Consolidated Health Economic Eva-
luation Reporting Standards (CHEERS) statement can be
used with any form of economic evaluation.
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challenges for editors, reviewers, and those who wish to scrutinise
a study’s findings [3]. There is evidence that the quality of reporting
of economic evaluations varies widely and could potentially benefit
from improved quality assurance mechanisms [4,5].
With the increasing number of publications available, and
opportunity costs from decisions based on misleading study
findings, transparency and clarity in reporting are important. In
addition, outside of economic evaluations conducted alongside
clinical trials, there are no widespread mechanisms for ware-
housing economic evaluation data to allow for independent
interrogation, such as ethics review proceedings, regulator dos-
siers, or study registries. Instead, independent analysis may rely
on the record keeping of individual investigators.
Even if measures to promote transparency exist, such as
registries, biomedical journal editors have increasingly promoted
and endorsed the use of reporting guidelines. Endorsement of
guidelines by journals for randomised controlled trials has been
shown to improve reporting [6]. The combination of the risk of
making costly decisions due to poor reporting with the lack of
mechanisms that promote accountability makes transparency in
reporting economic evaluations especially important and a pri-
mary concern among journal editors and decision makers [3,7].Aim and Scope
The aim of the Consolidated Health Economic Evaluation Report-
ing Standards (CHEERS) statement is to provide recommenda-
tions, in the form of a checklist, to optimise reporting of health
economic evaluations. The need for a contemporary reporting
guidance for economic evaluations was recently identified by
researchers and biomedical journal editors [8]. The CHEERS
statement attempts to consolidate and update previous efforts
[9–20] into a single useful reporting guidance.The primary audiences for the CHEERS statement are research-
ers reporting economic evaluations and the editors and peer
reviewers evaluating their publication potential. We hope the state-
ment (which consists of a 24 item checklist and accompanying
recommendations on the minimum amount of information to be
included when reporting economic evaluations) is a useful and
practical tool for these audiences and will improve reporting and, in
turn, health and healthcare decisions. To best understand and apply
the recommendations contained within the statement, we encour-
age readers to access the Explanation and Elaboration Report [21].Development of the CHEERS Statement
The statement was developed by a task force supported by the
International Society for Pharmacoeconomics and Outcomes
Research (ISPOR), as part of a broader initiative to facilitate and
encourage the interchange of expert knowledge and develop best
practices. The CHEERS Task Force members were chosen by the
chair of the task force primarily based on their longstanding
academic expertise and contribution to the multidisciplinary
field of health economic evaluation. In addition to four members
of the task force with doctorates in economics and its sub-
discipline of health economics (AHB, MD, JM, SP), members
included experts in health technology assessment and decision
making (FA, AHB, DH, MD, JM) and in clinical epidemiology and
biostatistics (AHB, EL, DM), those in active clinical practice (EL,
FA), and those with previous experience in reporting guideline
development (MD, DM). All members are researchers in applied
health and health policy, with five members currently serving as
editors for journals in the field (AHB, CC, MD, DG, EL).
The CHEERS Task Force followed current recommendations
for developing reporting guidelines [22]. Briefly, the need for new
guidance was first identified through a survey of members of the
World Association of Medical Editors. Of the 6% (55/965) who
responded, 91% (n¼50) indicated they would use a standard if one
were widely available [8]. Next, published checklists or guidance
documents related to reporting economic evaluations were iden-
tified from a systematic review and survey of task force members
[23]. Both of these activities were used to create a preliminary list
of items to include when reporting economic evaluations. Rec-
ommendations of the minimum set of reporting items were then
developed through a modified Delphi panel process. Forty eight
individuals identified by the task force with broad geographical
representation and representing academia, biomedical journal
editors, the pharmaceutical industry, government decision mak-
ers, and those in clinical practice were invited to participate.
Thirty seven agreed to participate. Participants were asked to
score importance on a Likert scale and the average scores,
weighted by each individual’s confidence in ability to score, were
then used to rank items. A cut-off point was applied to the
ranked list to determine the minimum number of items impor-
tant for reporting.
The CHEERS statement recommendations have been inde-
pendently reviewed and subsequently revised by task force
members. The recommendations are entirely those of the task
force—the sponsors of the study had no role in study design, data
analysis, data interpretation, or writing of the final recommen-
dations. A more complete description of the methods and
findings of the Delphi panel are found in the larger explanation
and elaboration document [21].Checklist Items
The final recommendations are subdivided into six main catego-
ries: (1) title and abstract; (2) introduction; (3) methods; (4) results;
Table 1 – CHEERS checklist—Items to include when reporting economic evaluations of health interventions.
Section/item Item
No
Recommendation Reported on
page No/ line
No
Title and abstract
Title 1 Identify the study as an economic evaluation or use more specific
terms such as ‘‘cost-effectiveness analysis’’, and describe the
interventions compared. _______________
Abstract 2 Provide a structured summary of objectives, perspective, setting,
methods (including study design and inputs), results (including
base case and uncertainty analyses), and conclusions. _______________
Introduction
Background and objectives 3 Provide an explicit statement of the broader context for the study.
Present the study question and its relevance for health policy or
practice decisions. _______________
Methods
Target population and subgroups 4 Describe characteristics of the base case population and subgroups
analysed, including why they were chosen. _______________
Setting and location 5 State relevant aspects of the system(s) in which the decision(s)
need(s) to be made. _______________
Study perspective 6 Describe the perspective of the study and relate this to the costs
being evaluated. _______________
Comparators 7 Describe the interventions or strategies being compared and state
why they were chosen. _______________
Time horizon 8 State the time horizon(s) over which costs and consequences are
being evaluated and say why appropriate. _______________
Discount rate 9 Report the choice of discount rate(s) used for costs and outcomes
and say why appropriate. _______________
Choice of health outcomes 10 Describe what outcomes were used as the measure(s) of benefit in
the evaluation and their relevance for the type of analysis
performed. _______________
Measurement of effectiveness 11a Single study-based estimates: Describe fully the design features of the
single effectiveness study and why the single study was a
sufficient source of clinical effectiveness data. _______________
11b Synthesis-based estimates: Describe fully the methods used for
identification of included studies and synthesis of clinical
effectiveness data. _______________
Measurement and valuation of
preference based outcomes
12 If applicable, describe the population and methods used to elicit
preferences for outcomes. _______________
Estimating resources and costs 13a Single study-based economic evaluation: Describe approaches used to
estimate resource use associated with the alternative
interventions. Describe primary or secondary research methods
for valuing each resource item in terms of its unit cost. Describe
any adjustments made to approximate to opportunity costs. _______________
13b Model-based economic evaluation: Describe approaches and data
sources used to estimate resource use associated with model
health states. Describe primary or secondary research methods for
valuing each resource item in terms of its unit cost. Describe any
adjustments made to approximate to opportunity costs. _______________
Currency, price date, and
conversion
14 Report the dates of the estimated resource quantities and unit costs.
Describe methods for adjusting estimated unit costs to the year of
reported costs if necessary. Describe methods for converting costs
into a common currency base and the exchange rate. _______________
Choice of model 15 Describe and give reasons for the specific type of decision-analytical
model used. Providing a figure to show model structure is strongly
recommended. _______________
Assumptions 16 Describe all structural or other assumptions underpinning the
decision-analytical model. _______________
Analytical methods 17 Describe all analytical methods supporting the evaluation. This
could include methods for dealing with skewed, missing, or
censored data; extrapolation methods; methods for pooling data;
approaches to validate or make adjustments (such as half cycle
corrections) to a model; and methods for handling population
heterogeneity and uncertainty. _______________
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Table 1 – continued
Section/item Item
No
Recommendation Reported on
page No/ line
No
Results
Study parameters 18 Report the values, ranges, references, and, if used, probability
distributions for all parameters. Report reasons or sources for
distributions used to represent uncertainty where appropriate.
Providing a table to show the input values is strongly
recommended. _______________
Incremental costs and outcomes 19 For each intervention, report mean values for the main categories of
estimated costs and outcomes of interest, as well as mean
differences between the comparator groups. If applicable, report
incremental cost-effectiveness ratios. _______________
Characterising uncertainty 20a Single study-based economic evaluation: Describe the effects of
sampling uncertainty for the estimated incremental cost and
incremental effectiveness parameters, together with the impact of
methodological assumptions (such as discount rate, study
perspective). _______________
20b Model-based economic evaluation: Describe the effects on the results of
uncertainty for all input parameters, and uncertainty related to
the structure of the model and assumptions. _______________
Characterising heterogeneity 21 If applicable, report differences in costs, outcomes, or cost-
effectiveness that can be explained by variations between
subgroups of patients with different baseline characteristics or
other observed variability in effects that are not reducible by more
information. _______________
Discussion
Study findings, limitations,
generalisability, and current
knowledge
22 Summarise key study findings and describe how they support the
conclusions reached. Discuss limitations and the generalisability
of the findings and how the findings fit with current knowledge. _______________
Other
Source of funding 23 Describe how the study was funded and the role of the funder in the
identification, design, conduct, and reporting of the analysis.
Describe other non-monetary sources of support. _______________
Conflicts of interest 24 Describe any potential for conflict of interest of study contributors in
accordance with journal policy. In the absence of a journal policy,
we recommend authors comply with International Committee of
Medical Journal Editors recommendations. _______________
For consistency, the CHEERS statement checklist format is based on the format of the CONSORT statement checklist.
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in a user friendly, 24 item checklist (Table 1) to aid users who wish
to follow them. A copy of the checklist can also be found
on the CHEERS Task Force website. (www.ispor.org/Task
Forces/EconomicPubGuidelines.asp). In order to encourage dissem-
ination and use of a single international standard for reporting, the
task force approached 14 journals identified as either the largest
publishers of economic evaluations or widely read by the medical
and research community. Thirteen journals responded, and 10
expressed their ability and interest in endorsing this guidance. The
CHEERS statement is being simultaneously published in BMC
Medicine, BMJ, BJOG: An International Journal of Obstetrics and Gynae-
cology, Clinical Therapeutics, Cost Effectiveness and Resource Allocation,
The European Journal of Health Economics, International Journal of
Technology Assessment in Health Care, Journal of Medical Economics,
Pharmacoeconomics, and Value in Health. To facilitate wider dissem-
ination and uptake of this reporting guidance, we encourage other
journals and groups to consider endorsing CHEERS.
Concluding Remarks
As the number of published health economic evaluations con-
tinues to grow, we believe more transparent and completereporting of methods and findings will be increasingly important
to facilitate interpretation and comparison of studies. We hope
the CHEERS statement, consisting of recommendations in a 24
item checklist, will be viewed as an effective consolidation and
update of previous efforts and serve as a starting point for
standard reporting going forward.
We believe the CHEERS statement represents a considerable
expansion over previous efforts. The strength of our approach is
that it was developed in accordance with current recommenda-
tions for the development of reporting guidelines, using an
international and multidisciplinary team of editors and content
experts in economic evaluation and reporting [22]. Similar to the
approach taken with other widely accepted guidelines, we have
defined a minimum set of criteria though a modified Delphi
technique and have translated these into recommendations, an
explanatory document with explanations, and a checklist. Unlike
some previous reporting guidance for economic evaluation, we
have also made every effort to be neutral about the conduct of
economic evaluation, allowing analysts the freedom to choose
different methods.
There may be several limitations to our approach. A larger
Delphi panel with a different composition could have led to a
different final set of recommendations [24]. Some less common
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tries, and system dynamicmodels) for conducting health economic
evaluation may not be well represented by our sample of experts.
Additionally, like many Delphi panel processes, we based decisions
to reject or accept criteria on arbitrary levels of importance.
However, we feel the group recruited to create the statement is
sufficiently knowledgeable of the more common applications of
economic evaluation, and the rules used to select criteria were
created a priori and are consistent with previous efforts.
We believe it will be important to evaluate the effects of
implementation of this statement and checklist on reporting in
future economic evaluations. As methods for the conduct of
economic evaluation continue to evolve, it will also be important
to revisit or extend the guidance. The CHEERS Task Force feels
that this statement should be reviewed for updating five years
from its release.Acknowledgements
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